Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies

NCT04278859 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

BIOLOGICAL: Drug: JS004, Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection Intravenous infusion

Sponsor

Shanghai Junshi Bioscience Co., Ltd.